Figure 3.
Figure 3. Apoptotic cells act independently of PGE2 and CD51 on DC migration but require complement and CD36. DCs were exposed to apoptotic Jurkat cells 4 hours before incubation with TNF-α (250 U/mL) or PGE2 (3.5 μg/mL and 7.0 μg/mL for 1 × PGE2 and 2 × PGE2, respectively) for 2 days. (A) Migration capacities of DCs tested using the Transwell migration assay. (B) Surface expression of CCR7 examined in total DC fractions by flow cytometry. Percentages of CCR7-positive cells as defined using isotype control (dashed line) are given. (C) DCs were incubated in 10% autologous complete or heat-inactivated serum, in the presence of 10 μg/mL blocking anti-CD51 or anti-CD36 antibodies for 30 minutes before the addition of PGE2 (□) or apoptotic Jurkat cells (▦). For clarity, specific migrations, normalized with the PGE2/TNFα/complete serum condition, are depicted (mean ± SD of 3 experiments). As in Figure 2C, specific migration represents the number of DCs migrating toward CCL21 minus the number of DCs migrating toward medium.

Apoptotic cells act independently of PGE2 and CD51 on DC migration but require complement and CD36. DCs were exposed to apoptotic Jurkat cells 4 hours before incubation with TNF-α (250 U/mL) or PGE2 (3.5 μg/mL and 7.0 μg/mL for 1 × PGE2 and 2 × PGE2, respectively) for 2 days. (A) Migration capacities of DCs tested using the Transwell migration assay. (B) Surface expression of CCR7 examined in total DC fractions by flow cytometry. Percentages of CCR7-positive cells as defined using isotype control (dashed line) are given. (C) DCs were incubated in 10% autologous complete or heat-inactivated serum, in the presence of 10 μg/mL blocking anti-CD51 or anti-CD36 antibodies for 30 minutes before the addition of PGE2 (□) or apoptotic Jurkat cells (▦). For clarity, specific migrations, normalized with the PGE2/TNFα/complete serum condition, are depicted (mean ± SD of 3 experiments). As in Figure 2C, specific migration represents the number of DCs migrating toward CCL21 minus the number of DCs migrating toward medium.

Close Modal

or Create an Account

Close Modal
Close Modal